Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 4/20 | 0.81 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.81 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.81 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.81 |
| ▸ | CA12 | O43570 | 3/20 | 0.70 |
| ▸ | CA1 | P00915 | 3/20 | 0.70 |
| ▸ | CA2 | P00918 | 3/20 | 0.70 |
| ▸ | CA7 | P43166 | 2/20 | 0.70 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.70 |
| ▸ | HTR2C | P28335 | 12/20 | 0.63 |
| ▸ | HTR2B | P41595 | 11/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11765973 | 0.98 | PNMT (0.78) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL1487047 | 0.89 | PNMT (1.00) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL4709338 | 0.89 | PNMT (0.87) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL30471185 | 0.89 | PNMT (0.87) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL29941551 | 0.89 | PNMT (1.00) | PNMTADRA2AADRA2BADRA2CCA12 | |
| Hydrochloric Acid SCHEMBL1038022 | 0.88 | PNMT (0.97) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL8879406 | 0.82 | CA1 (0.92) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL2011443 | 0.82 | CA1 (1.00) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL29519756 | 0.82 | CA1 (1.00) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL4030704 | 0.81 | PNMT (0.81) | PNMTADRA2AADRA2BADRA2CHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0229510-B1 | SULFINYL AND SULFONYL SUBSTITUTED-3-BENZAZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 1990-06-06 | — | — | EP | claimed |
| US-4824839-A | Sulfinyl and sulfonyl substituted 2,3,4,5 tetrahydro-1H-3-benzazepines and their use in treating gastrointestinal motility disorders | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-25 | — | — | US | claimed |
| EP-0229510-A1 | Sulfinyl and sulfonyl substituted-3-benzazepines | SMITHKLINE BEECHAM CORPORATION (US) | 1987-07-22 | — | — | EP | claimed |
| EP-1074549-B1 | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors | HOFFMANN LA ROCHE (CH) | 2003-11-19 | — | — | EP | disclosed |
| US-6218385-B1 | FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS | HOFFMANN-LA ROCHE INC. | 2001-04-17 | — | — | US | disclosed |
| EP-1074549-A2 | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-07 | — | — | EP | disclosed |
| EP-0229510-B1 | SULFINYL AND SULFONYL SUBSTITUTED-3-BENZAZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 1990-06-06 | — | — | EP | disclosed |
| US-4824839-A | Sulfinyl and sulfonyl substituted 2,3,4,5 tetrahydro-1H-3-benzazepines and their use in treating gastrointestinal motility disorders | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-25 | — | — | US | disclosed |
| WO-1988007858-A1 | SULFINYL AND SULFONYL SUBSTITUTED 3-BENZAZEPINES | SMITHKLINE BECKMAN CORPORATION (US) | 1988-10-20 | — | — | WO | disclosed |
| EP-0229510-A1 | Sulfinyl and sulfonyl substituted-3-benzazepines | SMITHKLINE BEECHAM CORPORATION (US) | 1987-07-22 | — | — | EP | disclosed |
| US-4024128-A | HYPOGLYCEMIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1977-05-17 | — | — | US | disclosed |